Aligos Therapeutics Inc
ALGS
NASDAQ
Biotechnology
$6.89
USD
+0.12 (+1.77%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $42.28M
Volume 66.7K
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 82 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
CEO
Dr. Lawrence Blatt
HQ
South San Francisco, CALIFORNIA, US
Founded
2020
Employees
82
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
6 metrics our research team weighs before forming a view on ALGS.
Based on Quantli research · SEC filings · as of Q1 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
43.9%
+120.2 pp
Gross Margin (TTM)
100.0%
0.0 pp
Operating Margin (TTM)
-2033.4%
+607.3 pp
Net Margin (TTM)
-1919.7%
-290.9 pp
ROE (TTM)
-284.1%
-238.4 pp
Free Cash Flow (TTM)
$-85.19M
—
Financial Snapshot
Revenue
$4.71M
+43.9%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-90.32M
-69.6%
YoY
Operating Cash Flow
$-84.72M
-7.4%
YoY
Key Statistics
Open
$6.77
Previous Close
$6.77
Day Range
$6.58 - $6.97
52 Week Range
$3.98 - $13.69
Volume
66.7K
Average Volume (10 Days)
210.0K
Dividend Yield
—
Valuation Measurement
Market Cap
$42.28M
P/E Ratio (TTM)
—
P/S Ratio (TTM)
8.99
Price / Book
1.33
Financial Highlights
Profit Margin
-1919.7%
Return on Assets
-139.9%
Return on Equity
-284.1%
Revenue (TTM)
$4.71M
Net Income (TTM)
$-90.32M
Diluted EPS (TTM)
-$8.75
Total Cash (MRQ)
$29.98M
Levered FCF (TTM)
$-85.19M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Earnings Calendar
Next Earnings
Estimated Q3 Release
Nov 04
Est. EPS
Adjusted consensus estimate
-$2.26
Analyst Consensus
Based on 2 analyst ratings
Avg Target: $32.50
(+371.7% upside)
High: $45.00 · Low: $20.00
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%